Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 60 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MWnLbY5ie2ViQYPzZZk> MUOyOEBp MYLJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? NUXZUoY3OjR4NEGxNFM>
COLO205 NU[yVVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojtO|IhcA>? M3T5VGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO Mn;lNlQ3PDFzMEO=
U937 NVz5XIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HFWVczKGh? MlPURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> NWPXc2JCOjR4NEGxNFM>
MOLM13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDBXndlPzJiaB?= NULtPYdSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MU[yOFY1OTFyMx?=
MOLM13 NGq3c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnJO|IhcA>? NWPCWYVnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB{d3KjZnXubYIuemW|aYP0ZY51KGi3bXHuJG1QVE1zMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW62bzDEUmEhf2m2aDDJR|UxKG:oIECuNFk3KM7:TR?= M1n3[VI1PjRzMUCz
MDA-MB-435 M4Dnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDhT4YzPCCq NI\OSI9KSzVyPUCuNVYh|ryP NH7hTo0yPThyMUizNS=>
K562 NVW0SmRQS3m2b4TvfIlkKEG|c3H5 M{T4Wlk3KGh? M4LKZ2ROW09? NV3XcGZzUUN3ME2yJO69VQ>? NYnHcIV{OjR2MUe1OlY>
DU145 NU[wXmtUS3m2b4TvfIlkKEG|c3H5 NEnYdFA6PiCq MluwSG1UVw>? NHKxTJlKSzVyPUeuOUDPxE1? NELwUGczPDRzN{W2Oi=>
MDA-MB-231 NX3ado5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG5OXoyKM7:TR?= M3u2WVI1KGh? Mn;QSG1UVw>? NWP3Zos3S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MYCyOFQyPzV4Nh?=
MCF7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITEZlIyKM7:TR?= M2TwN|I1KGh? NGjhXmtFVVOR M2PFTmNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> Moe5NlQ1OTd3Nk[=
MCF7 NY[zOpl3U2mwYYPlJGF{e2G7 NH3LSIk2KM7:TR?= M2e1flI1KGh? NFfV[YdFVVOR MnO2TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= MV[yOFQyPzV4Nh?=
MDA-MB-231 NUCzSVVjU2mwYYPlJGF{e2G7 NVXIeG9FPSEQvF2= NFnMWI0zPCCq MUHEUXNQ NH3kdW1KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw MX:yOFQyPzV4Nh?=
MDA-MB-231 NEHmTnJHfW6ldHnvckBCe3OjeR?= NWTsWIFYOS1zMDFOwG0> NFS0fHUzPCCq M2OzT2ROW09? MYTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? NULsOlNNOjR2MUe1OlY>
MCF7 MX\GeY5kfGmxbjDBd5NigQ>? NF:wcFEyNTFyIN88US=> MVeyOEBp NEfGTWFFVVOR NVzoephM\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MXuyOFQyPzV4Nh?=
MDA-MB-231 MWjGeY5kfGmxbjDBd5NigQ>? M2PQXFAvPS1zIN88US=> NVzPO4RkPDhiaB?= M3jzR2ROW09? M2Xnc4hieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm NWPiZ2V1OjR2MUe1OlY>
MCF7 NGfKZVRHfW6ldHnvckBCe3OjeR?= MWOwMlUuOSEQvF2= M1OySFQ5KGh? NHO3SopFVVOR M1LnXIhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm Mnu1NlQ1OTd3Nk[=
697 M13Wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;nbXNKSzVyPUG0PE4{QCCwTR?= NXHONHF6W0GQR1XS
P12-ICHIKAWA NEXrSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrHTWM2OD17Nj6wOEBvVQ>? NYDvdXBWW0GQR1XS
NB69 M13oTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2bY9KSzVyPUG2NU45KG6P MorLV2FPT0WU
EoL-1 NETVbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6WXVKSzVyPUG4O{4zPiCwTR?= NE\0[JlUSU6JRWK=
BHT-101 NH;UdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC0TWM2OD1zOUiuNlUhdk1? MVLTRW5ITVJ?
SK-NEP-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXWTWM2OD1{MkCuNFIhdk1? MX3TRW5ITVJ?
MHH-NB-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfXfWRFUUN3ME2yNlAvOTlibl2= M{fJdnNCVkeHUh?=
AsPC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD1{NUKuOVMhdk1? MmXkV2FPT0WU
ES1 NUnhc3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2TWM2OD1{NU[uNlUhdk1? NYTkRlJpW0GQR1XS
LAMA-84 NFzNSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KxbWlEPTB;MkW4MlE6KG6P NGrxXGRUSU6JRWK=
MOLT-16 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXtbJhVUUN3ME2yOVgvPDlibl2= Mn;jV2FPT0WU
ES7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ5Mz6wPUBvVQ>? NGLZd4ZUSU6JRWK=
KY821 NXu1XGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3c41WUUN3ME2zNVQvOSCwTR?= NIqwb3pUSU6JRWK=
RT-112 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LyVWlEPTB;M{KxMlA2KG6P MnPzV2FPT0WU
HL-60 NIn5eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjQVWx4UUN3ME2zOFAvPjZibl2= NGXkO4NUSU6JRWK=
MOLT-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4NWlEPTB;M{S1MlE{KG6P MmC4V2FPT0WU
KARPAS-45 Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInTV4ZKSzVyPUO3Ok4yPiCwTR?= MV3TRW5ITVJ?
SK-N-AS NFPDPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TKR2lEPTB;M{i3Mlg{KG6P NXHQSVBXW0GQR1XS
CTB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HkTGlEPTB;NEC1MlAzKG6P NV7WV2puW0GQR1XS
NKM-1 NEHJVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD12MUGuPFkhdk1? NUC0O24{W0GQR1XS
HTC-C3 M3G3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\BTnpKSzVyPUSzNk46PSCwTR?= M4HmcXNCVkeHUh?=
BE-13 NGjRNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHZTWM2OD12NESuNlchdk1? NYnOfIZjW0GQR1XS
KOSC-2 NVfPfo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrWU5hKSzVyPUS2Ok46KG6P M17pZXNCVkeHUh?=
NB14 NF3KPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3BXHVPUUN3ME20PFMvPThibl2= NWPEOYpkW0GQR1XS
CAL-27 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT5cJhxUUN3ME20PVQvPTlibl2= MX3TRW5ITVJ?
H9 NXLqZWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR7NT60N{BvVQ>? MXLTRW5ITVJ?
RS4-11 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjveHZKSzVyPUWwOE44OyCwTR?= NF3UT4ZUSU6JRWK=
PA-1 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HJdGlEPTB;NUC5Mlg3KG6P MnPCV2FPT0WU
MV-4-11 NEP1WodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XOZmlEPTB;NUGzMlg2KG6P MnmyV2FPT0WU
OS-RC-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljzTWM2OD13MkGuOlIhdk1? MXHTRW5ITVJ?
RPMI-8226 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1viNWlEPTB;NUK2Mlg3KG6P M4HJeXNCVkeHUh?=
HGC-27 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fSTmlEPTB;NU[0Mlk6KG6P MYTTRW5ITVJ?
CHP-212 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDKZlRKSzVyPUW5N{42QSCwTR?= MVPTRW5ITVJ?
NB10 NXGwb|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTV7OT6xPEBvVQ>? NIrPN|dUSU6JRWK=
HH M{XB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nvXmlEPTB;NUm5MlQ{KG6P M3S1OXNCVkeHUh?=
EW-16 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDKcodGUUN3ME22NFMvPTJibl2= M4fNeHNCVkeHUh?=
ES8 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfoXWR{UUN3ME22NFUvOjFibl2= NHX6UYxUSU6JRWK=
HAL-01 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XyNGlEPTB;NkC1MlY4KG6P MUTTRW5ITVJ?
A204 NVf5U2M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnSTWM2OD14M{OuPVEhdk1? NYTlUXBJW0GQR1XS
MHH-PREB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fpemlEPTB;NkO2Mlk6KG6P NYjFeJBXW0GQR1XS
EM-2 NWO3VYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W3WmlEPTB;NkWwMlY1KG6P NX3LdWg6W0GQR1XS
BV-173 NXvhbmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3npSmlEPTB;NkWyMlQ5KG6P MVHTRW5ITVJ?
ONS-76 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm5eXp2UUN3ME22O|cvQDJibl2= MX7TRW5ITVJ?
KM-H2 M2XXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;SO|B1UUN3ME22PVUvPTRibl2= MWnTRW5ITVJ?
D-263MG MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdzNz6xNkBvVQ>? M4DCPHNCVkeHUh?=
ES3 NVjYWnlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe2VpJKSzVyPUeyPE46OyCwTR?= NYTyNoliW0GQR1XS
VA-ES-BJ NXzNZoZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTd|Mj6yO{BvVQ>? MlHVV2FPT0WU
NBsusSR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTd2Mj65PUBvVQ>? NWrxVXdOW0GQR1XS
NCI-H520 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTd2Nj61NkBvVQ>? MkfhV2FPT0WU
ES5 M1r4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfyWm1KSzVyPUe1Nk45KG6P NFHMUFRUSU6JRWK=
T-24 NXXKToYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzVXmtRUUN3ME23O|gvPzFibl2= M4O1TXNCVkeHUh?=
SW962 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP5TWM2OD16MEiuOlMhdk1? MXjTRW5ITVJ?
EW-3 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjuXZNKSzVyPUiwPE44PiCwTR?= NIPycohUSU6JRWK=
RXF393 M3jDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThzMj63PUBvVQ>? NGi5dHRUSU6JRWK=
U251 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnsTWM2OD16MUOuPFghdk1? NX2yS5A{W0GQR1XS
CAMA-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3np[GlEPTB;OEOzMlk1KG6P NIDkOoxUSU6JRWK=
JVM-3 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[zRYFMUUN3ME24OVEvPzhibl2= M1ftXHNCVkeHUh?=
COLO-800 NX6wPHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPCWpBVUUN3ME24PVcvPzhibl2= NXzFSmJSW0GQR1XS
OVCAR-5 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjiZ5JDUUN3ME25NFAvOSCwTR?= MWPTRW5ITVJ?
LB1047-RCC MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5c|NJUUN3ME25NlcvPTZibl2= NIPVTlFUSU6JRWK=
SW954 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq4[FBCUUN3ME25NlkvPDFibl2= MVzTRW5ITVJ?
J-RT3-T3-5 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ryUmlEPTB;OUO2MlA3KG6P NHj3TGhUSU6JRWK=
Mewo MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fMeGlEPTB;OUO2MlYhdk1? M4nhTnNCVkeHUh?=
NCI-H1770 NWi3UIl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzmTWM2OD17NECuOVUhdk1? MkW4V2FPT0WU
HO-1-N-1 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzMUJlmUUN3ME25OlIvQDFibl2= MUnTRW5ITVJ?
HSC-3 NYHxN5ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TmeGlEPTB;OU[2MlQ5KG6P NVPnblJ4W0GQR1XS
TYK-nu M3\hWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Pid2lEPTB;OUm4MlI2KG6P NVu2cpY{W0GQR1XS
KYSE-150 NVzNbWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnjTWM2OD1zLkCwNFc3KM7:TR?= MVHTRW5ITVJ?
SN12C Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LrVGlEPTB;MT6wNFg4PSEQvF2= MYHTRW5ITVJ?
MOLT-13 M1Gydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMEG0NlEh|ryP MU\TRW5ITVJ?
TE-11 NH3kVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TxOWlEPTB;MT6wOFgyOiEQvF2= MonKV2FPT0WU
DB M4O5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\h[GFKSzVyPUGuNFczPzNizszN M1voR3NCVkeHUh?=
CAL-39 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvyW2ZZUUN3ME2xMlA4PTJ{IN88US=> M1n5NXNCVkeHUh?=
A3-KAW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrBTWM2OD1zLkC4OFA5KM7:TR?= M3;6WnNCVkeHUh?=
CHP-134 M3HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnKNnpIUUN3ME2xMlEyQDB5IN88US=> NXLER5I3W0GQR1XS
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vPWWlEPTB;MT6xNlM6PSEQvF2= NXL5SFB4W0GQR1XS
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwMUOxN|Qh|ryP M2HUPXNCVkeHUh?=
NCI-SNU-1 NIfCTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwMU[zOVQh|ryP NHvuR3ZUSU6JRWK=
CGTH-W-1 NHfwOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPLVYV5UUN3ME2xMlE4OTh4IN88US=> NXXQRVVzW0GQR1XS
MHH-ES-1 M3LT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTPZZpKSzVyPUGuNVc6QDZizszN NUPkd452W0GQR1XS
LB2241-RCC NFO4[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T6ZWlEPTB;MT6xPFYzKM7:TR?= MkHxV2FPT0WU
ML-2 NXjiRm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly4TWM2OD1zLkKwO|M1KM7:TR?= MlXSV2FPT0WU
COR-L23 M1n3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULlZlJNUUN3ME2xMlIzQTN|IN88US=> MmTpV2FPT0WU
BFTC-905 M{LTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTXRmFKUUN3ME2xMlI1OjZ5IN88US=> M4PwVHNCVkeHUh?=
Hs-578-T Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYVoxKSzVyPUGuNlU5OTdizszN Mmf3V2FPT0WU
KG-1 NUHsOlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTSTWM2OD1zLkK2Olg3KM7:TR?= MX7TRW5ITVJ?
HEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7iT5VKSzVyPUGuNlk{OzhizszN MmPQV2FPT0WU
A549 NG\y[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMkmzPVkh|ryP MmDDV2FPT0WU
COLO-741 NUjmW45RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3odGh[UUN3ME2xMlMzODh7IN88US=> M2fhSHNCVkeHUh?=
PC-3 NWfaeXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnjTWM2OD1zLkO1NlIyKM7:TR?= MmrDV2FPT0WU
HOS M2T6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL3fo94UUN3ME2xMlM2Ojl4IN88US=> NF;TSFhUSU6JRWK=
HT-1080 NHeyRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDBTWM2OD1zLkO3OVE6KM7:TR?= M4PvbnNCVkeHUh?=
TE-8 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q2OmlEPTB;MT60NVc4PCEQvF2= NF\IWXpUSU6JRWK=
BHY MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLnTWM2OD1zLkS2PVI{KM7:TR?= MnjPV2FPT0WU
BB65-RCC NYXQOnBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwNUC1Nlgh|ryP MYjTRW5ITVJ?
HN NWjCOmhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HnWmlEPTB;MT61OFA4OSEQvF2= NYfMVXNZW0GQR1XS
NCI-H441 M2f3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr3[JZKSzVyPUGuOVQ6ODdizszN NIC1VmJUSU6JRWK=
RPMI-8866 M{X0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwNUi1NFch|ryP MVXTRW5ITVJ?
CAL-62 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vKbGlEPTB;MT62NFg3OiEQvF2= M1zOdHNCVkeHUh?=
MG-63 NGfRdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrFRWZKSzVyPUGuOlE5OTNizszN M1PDSnNCVkeHUh?=
SK-LU-1 M1;3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwNkKxOVIh|ryP NYHkeVR6W0GQR1XS
BCPAP NXnlZ4huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvWOpBKSzVyPUGuOlY1PTdizszN MUTTRW5ITVJ?
22RV1 M3flNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M174SWlEPTB;MT62O|g1OyEQvF2= MX\TRW5ITVJ?
T47D NHjHdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwNkiwOlEh|ryP Mn3FV2FPT0WU
MSTO-211H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEexO5RKSzVyPUGuOlk3ODNizszN MX\TRW5ITVJ?
DEL NGn3dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4WIhKSzVyPUGuO|AzPzNizszN NFOzUZRUSU6JRWK=
H4 NYrDe|c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH6TWM2OD1zLkezNlEzKM7:TR?= NGftT4lUSU6JRWK=
CAL-51 M{G3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7hNFVTUUN3ME2xMlc1QDV3IN88US=> NG\GN|VUSU6JRWK=
ABC-1 NFHBcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TWcmlEPTB;MT63PFU5OiEQvF2= M32zTHNCVkeHUh?=
MZ2-MEL NVK5W5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwN{m1OFIh|ryP MnnwV2FPT0WU
YKG-1 NH75flNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwOEGwOlEh|ryP NEHiZ25USU6JRWK=
KM12 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe3TINKSzVyPUGuPFE3ODJizszN MXTTRW5ITVJ?
L-363 M1W2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H3XGlEPTB;MT64O|QyOiEQvF2= M2TS[HNCVkeHUh?=
KU812 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hn[mlEPTB;MT64PVI5OiEQvF2= Mn7WV2FPT0WU
LOXIMVI NU\GTJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33zdGlEPTB;MT65NVIzQCEQvF2= MnjTV2FPT0WU
G-401 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljnTWM2OD1zLkmyOFI5KM7:TR?= M2nCdXNCVkeHUh?=
SW780 NHLDb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHoTWM2OD1zLkm2NlQ3KM7:TR?= M3HGZ3NCVkeHUh?=
SW872 NEiyPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTqOmlKSzVyPUGuPVg{OyEQvF2= MWPTRW5ITVJ?
NB7 M3LKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm2TWM2OD1zLkm5N|I{KM7:TR?= NWXze|NwW0GQR1XS
T98G NV7ueG1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELtXJRKSzVyPUKuNFA3PjZizszN MlHOV2FPT0WU
SW1710 M{\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrXdYhpUUN3ME2yMlA3QTR3IN88US=> MmH3V2FPT0WU
NCI-H1573 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\WZmxKSzVyPUKuNFczQThizszN NYjTfIM2W0GQR1XS
KE-37 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4OlhKSzVyPUKuNFg6PTFizszN MnPtV2FPT0WU
786-0 NGDjTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX1TWM2OD1{LkG1OFM6KM7:TR?= M33zVXNCVkeHUh?=
SAS M2fmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTmTWM2OD1{LkKwN|c1KM7:TR?= M13pcXNCVkeHUh?=
CAL-54 M3;BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITHWFlKSzVyPUKuNlA1OTNizszN NXPmNIN6W0GQR1XS
SF268 M4XHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XhS2lEPTB;Mj6yN|EzOiEQvF2= NH3tTm9USU6JRWK=
SW620 NU\TPZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzUTWM2OD1{LkK2NVY6KM7:TR?= NEX4[5RUSU6JRWK=
MN-60 M{LNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwM{GwOkDPxE1? NEnCZYNUSU6JRWK=
EFO-27 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\FRWlEPTB;Mj6zNlA2QCEQvF2= MnnSV2FPT0WU
NCI-H747 NYK5dnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwM{KxPVkh|ryP MVjTRW5ITVJ?
HCC2218 NWHSc3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TQVmlEPTB;Mj6zOVM4PCEQvF2= MXnTRW5ITVJ?
MIA-PaCa-2 NUDPZ45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\OfWlEPTB;Mj6zOlQ{PyEQvF2= MYnTRW5ITVJ?
SJSA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrlO3lpUUN3ME2yMlM4Pzl4IN88US=> Ml;DV2FPT0WU
RKO MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1{LkO4OFk3KM7:TR?= NFTEVm5USU6JRWK=
NB6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rUdGlEPTB;Mj60NFM4PCEQvF2= MoXaV2FPT0WU
ES4 NX\lS3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf2TWM2OD1{LkS1OFIzKM7:TR?= NVntbI97W0GQR1XS
EGI-1 M{DQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTtc5JKSzVyPUKuOFY5QDNizszN MnOwV2FPT0WU
CTV-1 M4LXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNUK3O|Mh|ryP MWfTRW5ITVJ?
NCI-H1355 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNUW5OVEh|ryP NEf3RnlUSU6JRWK=
GT3TKB NVvXUYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\vTWM2OD1{LkW5NVk6KM7:TR?= NHjkZ3lUSU6JRWK=
SK-HEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XMVWlEPTB;Mj61PVI3PiEQvF2= MYfTRW5ITVJ?
GAMG MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWwc3hKSzVyPUKuOVk{QTRizszN MVHTRW5ITVJ?
SK-MES-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrETWM2OD1{Lk[xPFA{KM7:TR?= Ml3wV2FPT0WU
RO82-W-1 M2G4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwNkKwOVch|ryP MY\TRW5ITVJ?
ECC10 M1PnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\QOpRGUUN3ME2yMlcxOjB4IN88US=> NFLzb5BUSU6JRWK=
MCF7 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7OTYd7UUN3ME2yMlcyPDZ2IN88US=> NIqwVnBUSU6JRWK=
D-283MED M3v2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PaSmlEPTB;Mj63NlQ{KM7:TR?= MmDhV2FPT0WU
RPMI-7951 M4m5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJwN{W2PVQh|ryP MVTTRW5ITVJ?
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonVTWM2OD1{Lke3NFk6KM7:TR?= M1zQUnNCVkeHUh?=
KGN MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwOEG4PFQh|ryP MnSwV2FPT0WU
NUGC-3 M2fKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWeWlEPTB;Mj64NlUxPSEQvF2= MVXTRW5ITVJ?
NCI-H292 NXXreYh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[xW2lEPTB;Mj64OVA2OyEQvF2= NX72eXJEW0GQR1XS
Becker M{W0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPtTWM2OD1{Lkm1PFMzKM7:TR?= MYDTRW5ITVJ?
NCI-H1299 NHjrcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNwMEWyOlMh|ryP MmSyV2FPT0WU
ETK-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwMEW0N{DPxE1? NE\JVXdUSU6JRWK=
TK10 M1T5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj1TWM2OD1|LkKwNVY2KM7:TR?= NX;LNFk{W0GQR1XS
VMRC-RCZ M2Dyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwM{[0PFgh|ryP M1XBXXNCVkeHUh?=
YH-13 NEG2W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwNESwO|kh|ryP MnrNV2FPT0WU
DU-145 NELmcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITTcY5KSzVyPUOuOFYzPjlizszN MlG4V2FPT0WU
SW1088 M1nEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3m[3VKSzVyPUOuOFc1PyEQvF2= NGLueopUSU6JRWK=
HOP-92 NH\afolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;wdWlEPTB;Mz61NFM1OiEQvF2= MWfTRW5ITVJ?
KP-N-YS NWTLSYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrsNIk{UUN3ME2zMlYzOTN7IN88US=> MUfTRW5ITVJ?
NCI-H460 M{n6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPSW4VHUUN3ME2zMlY3PzNizszN MYTTRW5ITVJ?
U-2-OS NHnnfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XQWGlEPTB;Mz63NlU{PSEQvF2= NHvUV3dUSU6JRWK=
A101D NHHJZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLGTZJKSzVyPUOuO|Y6OzZizszN MoLpV2FPT0WU
MDA-MB-231 NVWyd|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;jcmlEPTB;Mz64NVk2OSEQvF2= NWG0OldoW0GQR1XS
IST-MES1 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHOSpNTUUN3ME2zMlg{OiEQvF2= NXnlPIVWW0GQR1XS
COR-L105 NVHjenlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzjeINKSzVyPUSuNFE5KM7:TR?= M{TrUXNCVkeHUh?=
NCI-H1437 NIX1RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4OplKSzVyPUSuNFI{ODJizszN NXTtd28zW0GQR1XS
CAL-85-1 M1ztVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XnNWlEPTB;ND6wNlQ3OSEQvF2= M1:2cHNCVkeHUh?=
MZ1-PC MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTxTFdEUUN3ME20MlE5PTV4IN88US=> M4O5S3NCVkeHUh?=
VM-CUB-1 M1nETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPGPHY4UUN3ME20MlMyOjh2IN88US=> M4PWSnNCVkeHUh?=
CHL-1 NUDMSnd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PjR2lEPTB;ND6zNlE3QSEQvF2= NFq2enBUSU6JRWK=
MDA-MB-361 NX35[2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD12LkOzNVU{KM7:TR?= NUnIU5l6W0GQR1XS
NCI-H661 M3K5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKxbIhIUUN3ME20MlUxODl{IN88US=> MkGxV2FPT0WU
EW-11 M3HJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4riUGlEPTB;ND61NlI{OSEQvF2= MYDTRW5ITVJ?
BEN M4O0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLwNG5LUUN3ME20MlUzQDF3IN88US=> MlXEV2FPT0WU
BFTC-909 M1n1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwNU[yO|Uh|ryP MmqxV2FPT0WU
NCI-H2087 M{j1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTVTWM2OD12LkW4NVY1KM7:TR?= M4exO3NCVkeHUh?=
RVH-421 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfBTWM2OD12Lk[2Olkh|ryP NUDLVWRtW0GQR1XS
P30-OHK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1cpE1UUN3ME20MlY5ODB6IN88US=> NH\vdnVUSU6JRWK=
NCI-H28 M4fnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHBemtbUUN3ME20MlgyPjZzIN88US=> NHXCWpZUSU6JRWK=
ES6 NWrpToQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\UfmNKSzVyPUSuPFMxOTZizszN NFLlUVRUSU6JRWK=
769-P MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTRwOEW5NlYh|ryP MUHTRW5ITVJ?
OE33 NELTXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XQemlEPTB;ND64PFE3OSEQvF2= NWHVeGFzW0GQR1XS
SW982 NYTObGJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke0TWM2OD12Lkm1NFYyKM7:TR?= MWjTRW5ITVJ?
A388 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjiOGtzUUN3ME21MlAzQTh|IN88US=> MXrTRW5ITVJ?
TI-73 NHXMUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DzbGlEPTB;NT6wOlE6PCEQvF2= MUXTRW5ITVJ?
HCT-116 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDLSFFKSzVyPUWuNFk5QDlizszN NX7Id2R5W0GQR1XS
HuP-T3 NXLwV2FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrmfJpkUUN3ME21MlE5PzB7IN88US=> NGjqVGVUSU6JRWK=
G-402 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fYcWlEPTB;NT6xPVQyPiEQvF2= NIe0[25USU6JRWK=
NCI-H1792 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rbWs{UUN3ME21MlI1PjJ{IN88US=> NUCxXWRyW0GQR1XS
NCI-H209 NEftT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTVwMkW5OFIh|ryP M2LEfXNCVkeHUh?=
NCI-H1650 M3XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXXTWM2OD13LkOwOlM1KM7:TR?= M3TyRnNCVkeHUh?=
LCLC-97TM1 M13TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjic2tKSzVyPUWuN|E5ODhizszN MV3TRW5ITVJ?
S-117 NVLzOVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwM{[5O|Yh|ryP MnH5V2FPT0WU
GI-ME-N M3r3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXSc3NYUUN3ME21MlM6PjhzIN88US=> M3:z[3NCVkeHUh?=
NCI-H2122 NGC0Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\OelVKSzVyPUWuOFk{QTdizszN M{PPN3NCVkeHUh?=
NCI-H1793 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PVVGlEPTB;NT62O|U6OyEQvF2= NFfUR4xUSU6JRWK=
C2BBe1 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWzTWM2OD13LkewNFg5KM7:TR?= NHvXV21USU6JRWK=
TE-12 M4XXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS3[m5KSzVyPUWuPFA2PTZizszN NEHZbZNUSU6JRWK=
LCLC-103H MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:x[mlEPTB;NT65NVch|ryP M37aXXNCVkeHUh?=
A673 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvTWM2OD13LkmxPVMzKM7:TR?= M1XlXHNCVkeHUh?=
BB30-HNC NW\6fmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoThTWM2OD13Lkm4N|Yh|ryP MUPTRW5ITVJ?
SF295 M{m5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPFRoJKUUN3ME22MlAxPDJ{IN88US=> NHjJb4ZUSU6JRWK=
KU-19-19 NH;Dd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[1ZoxKSzVyPU[uNFE4OzFizszN NHvUPG1USU6JRWK=
CFPAC-1 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jtfGlEPTB;Nj6wOFQ1OyEQvF2= MXLTRW5ITVJ?
LoVo MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZwMEWwOlMh|ryP MYnTRW5ITVJ?
8505C MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTZwMEe1O|Mh|ryP M4q0SXNCVkeHUh?=
GMS-10 NHy1PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;iRmlEPTB;Nj6xOVAxOiEQvF2= MWfTRW5ITVJ?
Ca9-22 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTZwMU[3NUDPxE1? M4PvbXNCVkeHUh?=
DOK MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX76VlZoUUN3ME22MlIzODd{IN88US=> NHzKb4pUSU6JRWK=
FADU M2\xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;RTWM2OD14LkK2NFM6KM7:TR?= NHjrS5lUSU6JRWK=
BxPC-3 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\YfmlEPTB;Nj6yO|MzKM7:TR?= MYXTRW5ITVJ?
CAL-33 NYjKN203T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7nNXpwUUN3ME22MlI6OjBzIN88US=> NV\vVlBKW0GQR1XS
SHP-77 NIHiZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrTWnZKSzVyPU[uN|E2OTJizszN MofMV2FPT0WU
LXF-289 NUj1V5dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZwM{O0OVUh|ryP M4ToPXNCVkeHUh?=
GB-1 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnZNoxTUUN3ME22MlM5OiEQvF2= MUDTRW5ITVJ?
KS-1 NXS2fWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTZwM{i0OFch|ryP MV3TRW5ITVJ?
D-502MG NVPkRYtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqeYdKSzVyPU[uOFI{PzZizszN MUDTRW5ITVJ?
LAN-6 NHXhSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX0OnVKSzVyPU[uOVExOjNizszN M3vhOnNCVkeHUh?=
H-EMC-SS NYLZ[o9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrsTWM2OD14LkW2NVQ4KM7:TR?= MUfTRW5ITVJ?
LC-2-ad NVXvfXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ryT2lEPTB;Nj62NFA4PiEQvF2= MXzTRW5ITVJ?
NCI-H1693 M1Szbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn74TWM2OD14Lk[yNlE2KM7:TR?= NHiwTGFUSU6JRWK=
SK-N-FI MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjseYVKSzVyPU[uO|UxPDRizszN NEf6cYtUSU6JRWK=
D-423MG NVHRXVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvIPXdKSzVyPU[uO|YyOTdizszN MoH2V2FPT0WU
KNS-42 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj5N|NKSzVyPU[uO|gyQTdizszN MXfTRW5ITVJ?
GCT M1XrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwOUO4JO69VQ>? M4LhN3NCVkeHUh?=
DSH1 NHzx[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f2bmlEPTB;Nz6wOlM{KM7:TR?= NHfkNmhUSU6JRWK=
D-247MG MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGyVVZ5UUN3ME23MlA4QDhzIN88US=> MYDTRW5ITVJ?
NCI-SNU-5 NEHvdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0TGlEPTB;Nz6xPFM4OSEQvF2= MmDUV2FPT0WU
TE-6 NX7OeVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDiTWM2OD15LkKwOlAyKM7:TR?= NVO1RVFTW0GQR1XS
NOMO-1 M{\l[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j5R2lEPTB;Nz6yNlEzPyEQvF2= NWnNS|ZIW0GQR1XS
NB17 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rmSGlEPTB;Nz6zNFMxQSEQvF2= MmS2V2FPT0WU
EW-22 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWwTWM2OD15LkO0N|Q5KM7:TR?= M2PjZ3NCVkeHUh?=
EW-13 NITDR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLXTWM2OD15LkO1NVYzKM7:TR?= MlrCV2FPT0WU
DOHH-2 NEPHWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS1NYVKSzVyPUeuOFQxOiEQvF2= MlnvV2FPT0WU
TGBC1TKB M{PZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj6TWM2OD15LkS5PFk6KM7:TR?= NI\Qc49USU6JRWK=
GR-ST M{\pbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTdwNUK1PVQh|ryP NG\YT3VUSU6JRWK=
KYSE-520 NILOZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfUTWM2OD15LkW1OVE2KM7:TR?= NWjJSJJ7W0GQR1XS
CAPAN-1 NWnBTWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLkcZNWUUN3ME23MlU6PTFizszN MUHTRW5ITVJ?
HCE-4 NFz6RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwZm5[UUN3ME23MlYzOjd7IN88US=> MlvUV2FPT0WU
MLMA NYX1N4lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW5TIdNUUN3ME23MlYzQTV5IN88US=> Mo\iV2FPT0WU
HT-144 NH7oSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnlTWM2OD15Lk[1N|Y5KM7:TR?= MVfTRW5ITVJ?
KYSE-180 M3;jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;OU2lEPTB;Nz63NVE3QSEQvF2= MV3TRW5ITVJ?
TE-5 NGTkW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DhUWlEPTB;Nz65OVk4OSEQvF2= M1;jVnNCVkeHUh?=
IGROV-1 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPETWM2OD15Lkm4OVUyKM7:TR?= NEPyfFNUSU6JRWK=
NCI-H1581 NE\2O4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRUGlEPTB;OD6wNVIh|ryP NFHTTXlUSU6JRWK=
SW1990 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRThwMES2OVkh|ryP M3\GOHNCVkeHUh?=
EFM-19 NEX1WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD0TWM2OD16LkC4OVQ2KM7:TR?= MV;TRW5ITVJ?
OGR-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LuXWlEPTB;OD60N|AzOyEQvF2= NHfhUGJUSU6JRWK=
U-118-MG NH;KZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRThwNEO0OlMh|ryP NUTFSGNNW0GQR1XS
SK-OV-3 NEfTWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnhTWM2OD16LkS2O|Y2KM7:TR?= NVn6U5J6W0GQR1XS
KNS-62 NW\Be4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\iNZNKSzVyPUiuOVE4PjFizszN NF\w[odUSU6JRWK=
GOTO M33i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftNWlEPTB;OD61O|Y{PSEQvF2= MkLOV2FPT0WU
8305C NW\COWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRThwN{C0PFQh|ryP MlTNV2FPT0WU
RPMI-2650 NFmxTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TtVWlEPTB;OD63NVk2PSEQvF2= NGXnTllUSU6JRWK=
NEC8 NIHYZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj3TWM2OD16Lke0N|A4KM7:TR?= NXKyOHNlW0GQR1XS
KYSE-450 NW\zeIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLVdm5nUUN3ME24Mlg3PTR6IN88US=> NWHOfXB1W0GQR1XS
RMG-I M33qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jT2lEPTB;OT6xOFA2QCEQvF2= NVK2W2NCW0GQR1XS
CAKI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4THc2lEPTB;OT6zNVk4QSEQvF2= NUnLcXd3W0GQR1XS
KYSE-510 NX3aVXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnQOWRKSzVyPUmuN|U4PzhizszN NE\DTppUSU6JRWK=
A4-Fuk MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nmfGlEPTB;OT6zOlcxOSEQvF2= MYDTRW5ITVJ?
AN3-CA M1rmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTlwNEW0OFQh|ryP NIjCVVJUSU6JRWK=
SK-N-DZ MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTlwN{K4OFkh|ryP M2XGUHNCVkeHUh?=
HSC-2 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITwN5lKSzVyPUmuO|Y3OjlizszN MmH2V2FPT0WU
EW-1 NUnWVJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorxTWM2OD17Lke5N|Y6KM7:TR?= NHHrdolUSU6JRWK=
D-566MG NVnE[Wl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwOEO2OlQh|ryP M3n3dnNCVkeHUh?=
COLO-792 M3Tx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuWJZKSzVyPUmuPVg4PDZizszN MmS5V2FPT0WU
TE-10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrlTWM2OD1zMD6wN|k3KM7:TR?= M2fzdHNCVkeHUh?=
NCI-H650 NVm5Vo5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyLkSyPFYh|ryP NXL1SXlRW0GQR1XS
U-266 M4XxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHVNJBKSzVyPUGwMlQ2PSEQvF2= M2\tPXNCVkeHUh?=
Detroit562 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV31ZmplUUN3ME2xNU4xPTF3IN88US=> MmTLV2FPT0WU
NH-12 M4PkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL0TWM2OD1zMT6xOFQ3KM7:TR?= NWmzNGc4W0GQR1XS
CO-314 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\4TWM2OD1zMT6yPFQzKM7:TR?= MWnTRW5ITVJ?
IST-MEL1 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfYTWM2OD1zMT61N|I{KM7:TR?= M3LDUHNCVkeHUh?=
KNS-81-FD MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFzLkW1Nlch|ryP M3K0VHNCVkeHUh?=
SW1463 M1[5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFzLkW5PFkh|ryP M1\0bnNCVkeHUh?=
NCI-H23 NV3uS5l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLk[1OVIh|ryP MUHTRW5ITVJ?
SK-MEL-2 NIfU[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6z[HVjUUN3ME2xNU44OTl5IN88US=> MkLLV2FPT0WU
NB13 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\WTWM2OD1zMj6xOFk2KM7:TR?= Mke0V2FPT0WU
Daoy M3vyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\NTWM2OD1zMj6yPFU3KM7:TR?= MmrZV2FPT0WU
NCI-H1623 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4fZZKSzVyPUGyMlM5ODFizszN MUDTRW5ITVJ?
NMC-G1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\qfGlEPTB;MUKuO|E4KM7:TR?= MlrYV2FPT0WU
DK-MG NEDzTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlntTWM2OD1zMj65OFgzKM7:TR?= NXXVZ4NVW0GQR1XS
TCCSUP MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfSbJBKSzVyPUGzMlEzQDRizszN NIDnfItUSU6JRWK=
SCC-15 M1zadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTnTWM2OD1zMz6yOlUyKM7:TR?= MmrjV2FPT0WU
NOS-1 NGS3THlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvmUGxIUUN3ME2xN{4zQDl|IN88US=> MXfTRW5ITVJ?
RH-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;0TWM2OD1zMz6zNFM4KM7:TR?= M3jmPHNCVkeHUh?=
SK-MEL-3 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF|LkO3Nlgh|ryP NIftZ2dUSU6JRWK=
NB5 M3fkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X5VGlEPTB;MUOuOFA3PyEQvF2= NEHKO2NUSU6JRWK=
SNU-387 NFr5PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESxOGlKSzVyPUGzMlUxPzJizszN MWfTRW5ITVJ?
CAL-120 M4i4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTzTWM2OD1zMz62O|E5KM7:TR?= NIXCRY5USU6JRWK=
Mo-T NYrBVHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULFfZp4UUN3ME2xN{44ODdizszN NVrTeFdDW0GQR1XS
LNCaP-Clone-FGC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT2U2Z{UUN3ME2xN{44QTl{IN88US=> MnmyV2FPT0WU
CAN NIP0cVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF2LkCyPFgh|ryP NWXJUllGW0GQR1XS
SK-MEL-30 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3IZWZoUUN3ME2xOE4xPjNizszN NWn3U5NYW0GQR1XS
COLO-678 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF2LkC4NlIh|ryP MnPrV2FPT0WU
SCC-9 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX0TWM2OD1zND6xNFIyKM7:TR?= NWnrb2FpW0GQR1XS
KINGS-1 M2TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHi[ldpUUN3ME2xOE4yPDB{IN88US=> NE\DZodUSU6JRWK=
SL-513 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLqTWM2OD1zND6xPFch|ryP M2D2eXNCVkeHUh?=
HLE NX;YPIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rZOWlEPTB;MUSuN|g2OiEQvF2= MX;TRW5ITVJ?
SW1573 NUHQZ5pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;tOGNKSzVyPUG0MlQ1OzVizszN MV3TRW5ITVJ?
KYSE-140 M{myRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe0cVRKSzVyPUG0MlY{OjdizszN M3nBZXNCVkeHUh?=
SK-PN-DW M2TrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVUGlEPTB;MUSuPFAxOSEQvF2= NIjiWXZUSU6JRWK=
A253 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwTZBKSzVyPUG1MlA3OjVizszN M3vHcnNCVkeHUh?=
CAL-12T M1nl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ETWM2OD1zNT60OlYzKM7:TR?= M3HNdnNCVkeHUh?=
COLO-679 NHHLTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{joemlEPTB;MUWuO|Y5OyEQvF2= M3PQfHNCVkeHUh?=
UACC-257 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnniTWM2OD1zNj6xNlAyKM7:TR?= MnqzV2FPT0WU
U-87-MG M2HXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF4LkO1NlMh|ryP M{LtTnNCVkeHUh?=
HCC1806 NH;FWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXPR5RDUUN3ME2xOk44ODdzIN88US=> MkGzV2FPT0WU
NCI-H2170 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GzZmlEPTB;MUeuNlQ1QCEQvF2= MoP6V2FPT0WU
AGS NITx[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LifWlEPTB;MUeuN|gxQCEQvF2= NWjjcYtUW0GQR1XS
MEL-HO NXHHOnVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF5Lke1NFMh|ryP MYjTRW5ITVJ?
SW48 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF5Lke3NVYh|ryP M4Tj[3NCVkeHUh?=
HuP-T4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD1zOD6wNlA3KM7:TR?= MXHTRW5ITVJ?
NCI-H720 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnuZYtJUUN3ME2xPE4yPDB{IN88US=> NUX1[Y1xW0GQR1XS
RCC10RGB MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLOe5hKSzVyPUG4MlE3QTdizszN MVjTRW5ITVJ?
HD-MY-Z MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWxOZZKSzVyPUG4MlIzPTRizszN MlTxV2FPT0WU
A427 NGG1dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5fGlEPTB;MUiuOVA6PCEQvF2= M2G5eXNCVkeHUh?=
HCC2998 M4j1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfsTWM2OD1zOD62NFUyKM7:TR?= MkjwV2FPT0WU
EPLC-272H Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi5eXJHUUN3ME2xPU4xPDN2IN88US=> M2XUdXNCVkeHUh?=
C32 NU\LdHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWxOHFHUUN3ME2xPU4xPDVizszN MoDIV2FPT0WU
UMC-11 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF7LkKxNlMh|ryP M3XjSnNCVkeHUh?=
CaR-1 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4TWM2OD1zOT62PFA1KM7:TR?= Ml;FV2FPT0WU
KYSE-410 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Dc|BKUUN3ME2xPU46OTN7IN88US=> NXPaNWdUW0GQR1XS
HuCCT1 M1H4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\GVmlEPTB;MkCuOlI6PCEQvF2= M4rnUXNCVkeHUh?=
LB996-RCC MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TreGlEPTB;MkCuO|E3QCEQvF2= M2LSdnNCVkeHUh?=
KYSE-70 M1y2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\wTWlEPTB;MkCuPFA2QSEQvF2= NVLnTXJKW0GQR1XS
CAL-72 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0VYpVUUN3ME2yNE46OTVizszN NX\EepVJW0GQR1XS
Capan-2 NH3yNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkTWM2OD1{MT6wOFE{KM7:TR?= MkDwV2FPT0WU
PANC-08-13 M4i5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3td5g{UUN3ME2yNU4zPTF3IN88US=> MUjTRW5ITVJ?
SBC-1 NF7LN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\oZXVlUUN3ME2yNU4{ODhzIN88US=> NIPWdVBUSU6JRWK=
MFM-223 NH;MZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13YRWlEPTB;MkGuN|M1OiEQvF2= MkKxV2FPT0WU
BB49-HNC NEnqSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrnfXdKSzVyPUKxMlU4OTZizszN NYf2dHZ3W0GQR1XS
SH-4 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmxfYFoUUN3ME2yNU43PjF6IN88US=> MVvTRW5ITVJ?
HuO9 M{nYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPRdo41UUN3ME2yNU46QDJ3IN88US=> M1P6eHNCVkeHUh?=
AM-38 NF;xSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz4U4lKSzVyPUKyMlA1QDVizszN MkXwV2FPT0WU
A431 NV7DeYxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:5coI6UUN3ME2yN{4zOTF7IN88US=> NFnUbmpUSU6JRWK=
YAPC NHHoOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ|LkK2OVEh|ryP NWLSOlUxW0GQR1XS
LU-139 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ZNpd5UUN3ME2yN{41QDB7IN88US=> Mn\oV2FPT0WU
HEC-1 NFjCXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP2enNtUUN3ME2yN{41QTN5IN88US=> M2jYfXNCVkeHUh?=
SCC-25 M3ntXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjSV2ZVUUN3ME2yOE4{ODB4IN88US=> NGnkR2lUSU6JRWK=
HT-29 NIPHSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zwfGlEPTB;MkSuN|gzOyEQvF2= MWnTRW5ITVJ?
PC-14 NHy4S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTw[5BFUUN3ME2yOE43PTdzIN88US=> MXLTRW5ITVJ?
Calu-6 NVHL[nRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDmTlUxUUN3ME2yOU42ODdzIN88US=> Ml7FV2FPT0WU
SJRH30 NWDadYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ3Lk[0PVYh|ryP MWrTRW5ITVJ?
ChaGo-K-1 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ4LkG2Nlkh|ryP M3PMRXNCVkeHUh?=
IA-LM MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ4LkO2OFUh|ryP MWPTRW5ITVJ?
GP5d M1u4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ4LkS0PVEh|ryP MkDpV2FPT0WU
NCI-H2291 M1LhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\LTWM2OD1{Nj62OVQyKM7:TR?= NUPZOHByW0GQR1XS
BALL-1 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:2dmlEPTB;Mk[uPVM6PyEQvF2= NUeyNVc3W0GQR1XS
HCC1954 NFfMXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3DepZKSzVyPUK2Mlk5ODhizszN NX7UbXd1W0GQR1XS
NCI-H2452 NUn2b3pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrKeXBKSzVyPUK3MlQyPjNizszN NYDSeod6W0GQR1XS
LU-99A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jFZ2lEPTB;MkeuOVU5OiEQvF2= MlLjV2FPT0WU
NTERA-S-cl-D1 NXH5NFRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[4[GlEPTB;MkeuO|I6QSEQvF2= Ml\JV2FPT0WU
PANC-10-05 M1y5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWwSY9KSzVyPUK3Mlc4PzVizszN NGLMV3FUSU6JRWK=
NCI-H2405 M3LPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q0Z2lEPTB;MkeuPVM5PyEQvF2= NX3UVlZRW0GQR1XS
MDA-MB-415 M{\uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTETWM2OD1{OD60NVM4KM7:TR?= MV\TRW5ITVJ?
NCI-H2342 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHroPFlKSzVyPUK4MlUzQDFizszN NH\CVFVUSU6JRWK=
TGBC24TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrFTWM2OD1{OD63NVE4KM7:TR?= NEfNS4JUSU6JRWK=
LU-134-A Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UNHdKSzVyPUK4MlkzPjFizszN M4PScnNCVkeHUh?=
SCC-4 M2L3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT1SJRKSzVyPUOxMlA1QTRizszN NVq5bZNSW0GQR1XS
Saos-2 M3PtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNzLkmzNFYh|ryP M{T3SXNCVkeHUh?=
RERF-LC-MS NVfoeYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH1TWM2OD1|Mj64NlMyKM7:TR?= NW\q[JozW0GQR1XS
M14 NIfKNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDKcIRKSzVyPUOyMlk4PjRizszN MkfPV2FPT0WU
HPAF-II M3\xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\iTWM2OD1|Mz61NFEyKM7:TR?= M4L2bXNCVkeHUh?=
NCI-H1755 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN2LkOzNFUh|ryP Mnf6V2FPT0WU
D-392MG M2fQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkSmpKSzVyPUO1Mlg3PzRizszN MmHjV2FPT0WU
A704 NEm5cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN4LkC0Nlch|ryP MX7TRW5ITVJ?
CP50-MEL-B NWLqbI1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfIfZJTUUN3ME2zOk4yQTFzIN88US=> NGHPZ2dUSU6JRWK=
EW-18 M2HNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX2[IdKSzVyPUO2MlQ2OiEQvF2= MorIV2FPT0WU
WM-115 NXPLPVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXuTWM2OD1|Nj64NFk6KM7:TR?= MV3TRW5ITVJ?
LU-65 NWmxOmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jVPWlEPTB;M{euNVQyPyEQvF2= NHT0VpZUSU6JRWK=
NCI-H1563 NF;jPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN5LkK0PFQh|ryP NWDufotrW0GQR1XS
DBTRG-05MG NFX6ZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN6LkC2PVEh|ryP MV3TRW5ITVJ?
NCI-H630 M{jGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqzTWM2OD1|OD60O|E1KM7:TR?= M1\3bXNCVkeHUh?=
NCI-H1155 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rOW2lEPTB;M{muNlQzKM7:TR?= NEX0RnBUSU6JRWK=
OVACR-3 M3ywVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN7LkmxPVUh|ryP MkPWV2FPT0WU
OAW-42 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfscXpKSzVyPUSwMlQzPThizszN NGDBXFdUSU6JRWK=
JVM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRzLkK0NVUh|ryP MmjRV2FPT0WU
C3A NYLIWXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjJ[YJnUUN3ME20NU4{PDR5IN88US=> Mnj1V2FPT0WU
HT55 NG\5WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiNHZKSzVyPUSyMlI5PDFizszN M2m5bXNCVkeHUh?=
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV72eVBIUUN3ME20Nk4zQTd2IN88US=> MnL6V2FPT0WU
MEG-01 NG\vWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR{LkS2NVYh|ryP NH3hSYdUSU6JRWK=
NCI-H82 NWr5fHM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDyOYNKSzVyPUSzMlk5QTJizszN MUnTRW5ITVJ?
JEG-3 M17POWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR2Lkm0O{DPxE1? NVXwVYZjW0GQR1XS
BPH-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\VOHdSUUN3ME20Ok4{QTl6IN88US=> NWrteIxoW0GQR1XS
MPP-89 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XEdGlEPTB;NEeuNlg6QCEQvF2= Mk\lV2FPT0WU
ALL-PO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR5LkSxPFgh|ryP MVPTRW5ITVJ?
HT NHrvSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vb2FKSzVyPUS3MlQ6OiEQvF2= MkDJV2FPT0WU
NCI-H2347 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPFNZVKSzVyPUS4MlA4OTVizszN MojOV2FPT0WU
A2780 NEHDZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W3RmlEPTB;NEmuOFIzQCEQvF2= NWi1Om1NW0GQR1XS
KARPAS-299 NXXLenBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2eIh4UUN3ME20PU42OTF7IN88US=> NGH5TXRUSU6JRWK=
NCI-H1651 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP1TWM2OD12OT64PFIyKM7:TR?= NFjKVFJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; 

PubMed: 30300583     


Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells.

pRb(S807, 811) / CDK4 / CDK6 / PARP; 

PubMed: 28453226     


Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. 

LC3-I / LC3-II; 

PubMed: 28453226     


Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. 

pAMPKα(T172) / pULK1(S317); 

PubMed: 28453226     


Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. 

SMAD2 (pS255); 

PubMed: 30343527     


T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.

30300583 28453226 30343527
Growth inhibition assay
Cell viability; 

PubMed: 29670090     


Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.

29670090
Immunofluorescence
SAHF/ATRX; 

PubMed: 26988987     


DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. 

LC3B; 

PubMed: 28453226     


LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).

26988987 28453226
ELISA
PGE2; 

PubMed: 26540629     


The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.

26540629
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Drug: Palbociclib|Other: locoregional treatment Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer October 15 2019 Not Applicable
NCT03900884 Not yet recruiting Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole Breast Neoplasm Female Peter MacCallum Cancer Centre Australia September 2019 Phase 1
NCT03844997 Recruiting Drug: Palcociclib|Drug: CPX-351 Acute Myeloid Leukemia|AML Aziz Nazha|Case Comprehensive Cancer Center May 31 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID